Patients with Diabetes Fare Worse After MI Than Those Without Diabetes

Improvements in treatment have not narrowed the mortality gap between diabetic and nondiabetic ACS patients.

Individuals with diabetes are known to be at high risk for cardiovascular events. However, it remains unclear whether diabetic patients fare worse than nondiabetic patients across the full spectrum of acute coronary syndromes and with the benefit of contemporary treatment strategies. To compare differences in outcomes between diabetic and nondiabetic patients, investigators pooled data from 11 Thrombolysis in Myocardial Infarction (TIMI) clinical ACS trials conducted between 1997 and 2006. The primary outcomes of interest were mortality at 30 days and at 1 year.

Of the 62,036 patients included in the analysis, 10,613 had diabetes. At 30 days and 1 year, mortality rates were significantly higher for diabetic patients than for nondiabetic pati…

Reviewing Author

JoAnne M. Foody, MD

Disclosures

Consultant / Advisory boardAegerion; Amarin; Bristol-Myers Squibb; Janssen; Merck; Pfizer; Sanofi-Aventis; Boehringer Ingelheim

Leadership positions in professional societiesAmerican College of Cardiology, Cardiosmart (Co-chair)

JoAnne M. Foody, MD

Disclosures

Consultant / Advisory boardAegerion; Amarin; Bristol-Myers Squibb; Janssen; Merck; Pfizer; Sanofi-Aventis; Boehringer Ingelheim

Leadership positions in professional societiesAmerican College of Cardiology, Cardiosmart (Co-chair)

Patients with Diabetes Fare Worse After MI Than Those Without Diabetes

Topics

Reviewing Author